Literature DB >> 20921314

Serotype distribution and susceptibility of Streptococcus pneumoniae isolates from pleural fluid in Spain from 1997 to 2008.

A Fenoll1, L Aguilar, M D Vicioso, M J Gimenez, O Robledo, J J Granizo, C Mendez.   

Abstract

Trends in serotype incidence and susceptibility (1997 to 2008) of Spanish Streptococcus pneumoniae pleural isolates (n = 831) were explored. Penicillin (oral) nonsusceptibility rates and the incidence of 7-valent pneumococcal conjugate vaccine (PCV-7) serotypes showed decreasing trends (R(2) ≥ 0.600; P ≤ 0.002). The incidence of serotypes 1 and 19A showed increasing trends (R(2) ≥ 0.759; P < 0.001), with no trends for serotype 3. Serotypes 19A, 1, and 3 represented 85% of pediatric isolates in 2008. In serotype 19A, the penicillin nonsusceptibility rate was 82.4% in 2008, associated with amoxicillin and cefotaxime nonsusceptibility in 21.4% of isolates. Inclusion of these serotypes in new vaccines offers the broadest coverage.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20921314      PMCID: PMC2981252          DOI: 10.1128/AAC.00217-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates causing systemic infections in Spain, 1979-1989.

Authors:  A Fenoll; C Martín Bourgon; R Muñóz; D Vicioso; J Casal
Journal:  Rev Infect Dis       Date:  1991 Jan-Feb

2.  Susceptibility of pneumococci causing meningitis in Spain and prevalence among such isolates of serotypes contained in the 7-valent pneumococcal conjugate vaccine.

Authors:  Asunción Fenoll; María-José Giménez; María-Dolores Vicioso; Juan-José Granizo; Olga Robledo; Lorenzo Aguilar
Journal:  J Antimicrob Chemother       Date:  2009-10-14       Impact factor: 5.790

3.  Molecular epidemiology of pediatric pneumococcal empyema from 2001 to 2007 in Utah.

Authors:  Carrie L Byington; Kristina G Hulten; Krow Ampofo; Xiaoming Sheng; Andrew T Pavia; Anne J Blaschke; Melinda Pettigrew; Kent Korgenski; Judy Daly; Edward O Mason
Journal:  J Clin Microbiol       Date:  2009-12-16       Impact factor: 5.948

4.  Has the licensing of respiratory quinolones for adults and the 7-valent pneumococcal conjugate vaccine (PCV-7) for children had herd effects with respect to antimicrobial non-susceptibility in invasive Streptococcus pneumoniae?

Authors:  A Fenoll; L Aguilar; J J Granizo; M J Giménez; L Aragoneses-Fenoll; C Mendez; D Tarragó
Journal:  J Antimicrob Chemother       Date:  2008-09-26       Impact factor: 5.790

5.  Empyema hospitalizations increased in US children despite pneumococcal conjugate vaccine.

Authors:  Su-Ting T Li; Daniel J Tancredi
Journal:  Pediatrics       Date:  2009-11-30       Impact factor: 7.124

6.  Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.

Authors:  Cynthia G Whitney; Monica M Farley; James Hadler; Lee H Harrison; Nancy M Bennett; Ruth Lynfield; Arthur Reingold; Paul R Cieslak; Tamara Pilishvili; Delois Jackson; Richard R Facklam; James H Jorgensen; Anne Schuchat
Journal:  N Engl J Med       Date:  2003-05-01       Impact factor: 91.245

7.  Emergence of a multidrug-resistant clone (ST320) among invasive serotype 19A pneumococci in Spain.

Authors:  Carmen Ardanuy; Dora Rolo; Asunción Fenoll; David Tarrago; Laura Calatayud; Josefina Liñares
Journal:  J Antimicrob Chemother       Date:  2009-06-17       Impact factor: 5.790

8.  Clinical features, aetiology and outcome of empyema in children in the north east of England.

Authors:  K M Eastham; R Freeman; A M Kearns; G Eltringham; J Clark; J Leeming; D A Spencer
Journal:  Thorax       Date:  2004-06       Impact factor: 9.139

9.  Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine.

Authors:  Carmen Muñoz-Almagro; Iolanda Jordan; Amadeo Gene; Cristina Latorre; Juan J Garcia-Garcia; Roman Pallares
Journal:  Clin Infect Dis       Date:  2008-01-15       Impact factor: 9.079

10.  Pediatric parapneumonic empyema, Spain.

Authors:  Ignacio Obando; Carmen Muñoz-Almagro; Luis A Arroyo; David Tarrago; David Sanchez-Tatay; David Moreno-Perez; Sahar S Dhillon; Cristina Esteva; Susanna Hernandez-Bou; Juan J Garcia-Garcia; William P Hausdorff; Angela B Brueggemann
Journal:  Emerg Infect Dis       Date:  2008-09       Impact factor: 6.883

View more
  3 in total

1.  The Alere BinaxNOW Pneumococcal Urinary Antigen Test: Diagnostic Sensitivity for Adult Pneumococcal Pneumonia and Relationship to Specific Serotypes.

Authors:  Hisashi Shoji; Arnau Domenech; Antonella Francesca Simonetti; Aida González; Dolores García-Somoza; Meritxell Cubero; Sara Martí; Masayuki Maeda; Fe Tubau; Josefina Liñares; Maria Angeles Domínguez; Jordi Carratalà; Carmen Ardanuy
Journal:  J Clin Microbiol       Date:  2018-01-24       Impact factor: 5.948

Review 2.  Cefditoren in upper and lower community-acquired respiratory tract infections.

Authors:  Francisco Soriano; María-José Giménez; Lorenzo Aguilar
Journal:  Drug Des Devel Ther       Date:  2011-02-09       Impact factor: 4.162

3.  Invasive pneumococcal disease in healthy adults: increase of empyema associated with the clonal-type Sweden(1)-ST306.

Authors:  Imma Grau; Carmen Ardanuy; Laura Calatayud; Dora Rolo; Arnau Domenech; Josefina Liñares; Roman Pallares
Journal:  PLoS One       Date:  2012-08-13       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.